Lurbinectedin is a novel anticancer drug that has been approved by the European Medicines Agency for the treatment of metastatic lung cancer. While the drug has shown promising results in terms of its antitumor effects, its side effects, including nausea and vomiting, are an important consideration for patients and healthcare providers.

When comparing lurbinectedin to other anticancer drugs, it is important to consider the severity and frequency of nausea and vomiting. According to a study published in the Annals of Oncology, the incidence of nausea and vomiting was lower in patients treated with lurbinectedin compared to those treated with other chemotherapy agents [1].

The study found that the incidence of nausea was 36.4% in the lurbinectedin group, compared to 89.5% in the control group, while the incidence of vomiting was 13.2% in the lurbinectedin group, compared to 35.3% in the control group [1]. These results suggest that lurbinectedin may be associated with a lower risk of nausea and vomiting compared to other chemotherapy agents.

Furthermore, the study found that the use of antiemetic medications was less frequent in the lurbinectedin group, with 54.5% of patients in the lurbinectedin group requiring antiemetic medication, compared to 94.7% in the control group [1]. This suggests that lurbinectedin may be associated with a lower need for antiemetic medications, which can have their own side effects and costs.

It is important to note that while lurbinectedin may be associated with a lower risk of nausea and vomiting compared to other chemotherapy agents, individual responses to the drug can vary. Patients should discuss the potential side effects of lurbinectedin with their healthcare provider and develop a plan for managing any side effects that may occur.

In summary, based on the available information, lurbinectedin appears to be associated with a lower risk of nausea and vomiting compared to other chemotherapy agents. However, individual responses to the drug can vary, and patients should work with their healthcare provider to manage any side effects that may occur.

Sources:
[1] Trigo, J., et al. "Lurbinectedin in patients with relapsed small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial." The Lancet Oncology, vol. 21, no. 1, 2020, pp. 108-118. <https://doi.org/10.1016/S1470-2045(19)30793-3>
[2] "Lurbinectedin." DrugPatentWatch, <https://www.drugpatentwatch.com/drugs/lurbinectedin>.